{"product_id":"luciseta-sparsentan","title":"LuciSeta (Sparsentan)","description":"\u003ch2\u003eAbout Sparsentan\u003c\/h2\u003e\u003cp\u003eSparsentan is a medication used for the treatment of primary immunoglobulin A nephropathy.Sparsentan is an endothelin and angiotensin II receptor antagonist.\u003c\/p\u003e\u003ch3\u003eIgA Nephropathy\u003c\/h3\u003e\u003cp\u003eIndicated to slow kidney function decline in adults with primaryimmunoglobulin A nephropathy (IgAN) who are at risk for disease progression\u003c\/p\u003e\u003cp\u003e200 mg PO qDay initially; after 14 days, increase to recommended dose of 400 mg qDay, as tolerated\u003c\/p\u003e\u003cp\u003eWhen resuming treatment after an interruption, consider starting at 200 mg\/day, then after 14 days, increase to 400 mg\/day\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eALT\/AST \u0026gt;3x to ≤8x ULN\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eConfirm elevation with repeat measure\u003c\/li\u003e\n\u003cli\u003eIf confirmed, interrupt treatment, and monitor ALT\/AST levels and bilirubin at least weekly, and INR as needed, until levels return to pretreatment values and the patient is asymptomatic\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eDo not resume treatment if any of the following occurs without other cause found\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eALT\/AST \u0026gt;3x ULN and total bilirubin \u0026gt;2x ULN or INR \u0026gt;1.5\u003c\/li\u003e\n\u003cli\u003eALT\/AST \u0026gt;3x ULN, with symptoms of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and\/or eosinophilia (\u0026gt;5% eosinophils)\u003c\/li\u003e\n\u003cli\u003eALT\/AST \u0026gt;5x ULN for \u0026gt;2 weeks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003eIf treatment resumed, initiate at 200 mg qDay, with reassessment of hepatic enzyme levels and bilirubin within 3 days; close monitoring required in these patients\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eALT\/AST \u0026gt;8 x ULN\u003c\/h4\u003e\u003cul\u003e\u003cli\u003ePermanently discontinue if no other cause found\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eCoadministration of strong CYP3A4 inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf use is unavoidable, interrupt sparsentan\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (eGFR 30-89 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e): No clinically significant differences in pharmacokinetics observed\u003c\/li\u003e\n\u003cli\u003eSevere (eGFR \u0026lt;30 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eMild, moderate, or severe (Child-Pugh A-C): Avoid use with any hepatic impairment because of risk of serious liver injury\u003c\/li\u003e\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797956063275,"sku":"RL20250101s1400","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1369.jpg?v=1787022249","url":"https:\/\/xomeds.com\/products\/luciseta-sparsentan","provider":"XOMEDS","version":"1.0","type":"link"}